EXPLORE THE SCIENCE
TL;DR: A 2026 preprint in medRxiv used electroencephalography (EEG), a scalp electrical-activity recording method, and electrocardiogram (ECG) recordings to test whether brain-heart interplay, meaning coupling between brain-network organization and cardiac aut…
Read article
TL;DR: A 2026 study in Glia used human single-nucleus RNA sequencing datasets and mouse validation to identify a shared neurodegeneration-linked microglial transcription program, highlighting SPP1 as a disease-associated microglia marker. Key Findings Five dis…
Read article
TL;DR: A 2026 Neurological Sciences study followed 216 early Parkinson’s patients for 2 years after levodopa started and found that several non-motor symptom differences between men and women persisted or emerged despite adjustment for baseline scores and levo…
Read article
TL;DR: A 2026 medRxiv preprint linked pre-surgery diffusion MRI markers in Parkinson’s disease to 6-month changes in impulsive-compulsive behaviour after subthalamic deep brain stimulation. Key Findings Small DBS cohort: Researchers followed 35 Parkinson’s dis…
Read article
TL;DR: A 2026 medRxiv preprint found psychomotor retardation, meaning slowed movement, speech, and thinking during depression, was linked to higher later Parkinson’s diagnosis risk in 6,327 London mental-health records. Key Findings Psychomotor retardation was…
Read article
TL;DR: A 2026 study in Molecular Neurobiology found that Antrodia cinnamomea, a medicinal fungus extract, worked best when carried on citrate-stabilized silver nanoparticles in cell and rat models of Parkinson’s-like dopamine injury. Key Findings 6-OHDA create…
Read article
TL;DR: A 2026 npj Parkinson’s Disease study used brain transcriptome data and genome-scale metabolic modeling to predict Parkinson’s metabolite biomarkers, including dopamine-related changes, and separated 104 postmortem samples into three metabolic clusters.…
Read article
TL;DR: A 2026 preprint on medRxiv using the Harvard Biomarkers Study found that 43% of Parkinson’s disease patients had depression, anxiety, sleep apnea, or restless legs syndrome, compared with 21% of controls. Key Findings 1,224-person cohort: Researchers an…
Read article
TL;DR: A 2026 systematic review and exploratory network meta-analysis of 5 randomized trials in Neurological Sciences found dose-specific ON-medication motor improvements, measured while usual Parkinson’s drugs were active, for some GLP-1 receptor agonists, gl…
Read article
TL;DR: A 2026 medRxiv preprint found that alpha-synuclein seed-positive Parkinson’s patients had slower ON-medication motor progression, measured while usual Parkinson’s medication was active, and more sustained levodopa responsiveness than matched seed-negati…
Read article